Swiss Re (SREN) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
8 Jul, 2026Strategic priorities and transformation
Addressed recurring earnings drags by cleaning underperforming portfolios, increasing U.S. casualty reserves, and reinforcing technical underwriting, data-driven decision-making, and talent initiatives.
Implemented a four-phase strategy, including immediate actions like iptiQ withdrawal, comprehensive reserve review, and a midterm ambition to set a new strategic North Star.
Focused on cost efficiency, targeting $300 million in operating cost savings by 2027, with $100 million realized by 2025.
Prioritized capital strength, maintaining a robust SST ratio and aiming for a 7%+ annual dividend per share increase over the next three years.
Maintained strong capitalisation and financial flexibility, with a focus on superior capital management.
Financial guidance and targets
Set a 2025 net income target of more than $4.4 billion, up from the previous $3.6 billion for 2024, reflecting a 22% increase.
Improved combined ratio targets for 2025: P&C Reinsurance to 85 or better, Corporate Solutions to better than 91.
Life & Health earnings target raised to $1.6 billion for 2025, with CSM release guidance adjusted to 8%.
Long-term return on equity aspiration remains above 14%.
No additional capital return (e.g., share buybacks) planned in the near term, focusing on dividend growth and business investment.
Portfolio management and reserving actions
Reduced exposure to U.S. casualty and large corporate risks, with total reserves for U.S. liability increasing from $10 billion to $13 billion in nine months and $3.1 billion added in 9M 2024.
Adopted a prudent reserving approach, positioning at the 90th percentile of best estimate range and maintaining an uncertainty load, especially in P&C Re.
No net prior year reserve releases expected in 2025; uncertainty load for P&C Re to be about $500 million.
iptiQ EMEA P&C business sold to Allianz Direct, with other iptiQ portfolios in runoff or under review, reducing net loss to ~$50m by 2027.
Business mix shifting toward shorter-tail lines, benefiting combined ratio over time.
Latest events from Swiss Re
- Q1 2025 net income of USD 1.3bn and 22.4% ROE achieved, with strong capital and investment gains.SREN
Q1 20259 Jul 2026 - All AGM proposals passed, with strong financials, higher dividend, and new board members confirmed.SREN
AGM 20259 Jul 2026 - Net income reached USD 3.2 billion in 2024, with a 15% ROE and 8% dividend increase proposed.SREN
Q4 20248 Jul 2026 - Q1 2026 net income rose 19% to USD 1.5bn, with 24% ROE and improved combined ratios.SREN
Q1 20267 May 2026 - Record earnings, higher dividend, and strategic focus on sustainability and risk approved.SREN
AGM 202610 Apr 2026 - Record USD 4.8B net income, 19.6%–20% ROE, and strong capital returns with resilient outlook.SREN
Q4 20259 Apr 2026 - Record USD 4.8bn net income, USD 1.5bn buyback, and 9% dividend hike; 2026 targets reflect normalization.SREN
Q4 2025 (Media)7 Apr 2026 - Record FY 2025 net income and strong capital position support higher dividends and share buybacks.SREN
Corporate presentation20 Mar 2026 - Net income rose to USD 2.1bn in H1 2024, with strong underwriting and investment returns.SREN
Q2 202423 Jan 2026